CN1972593A - 干扰rna在生产转基因动物中的用途 - Google Patents

干扰rna在生产转基因动物中的用途 Download PDF

Info

Publication number
CN1972593A
CN1972593A CNA200480040601XA CN200480040601A CN1972593A CN 1972593 A CN1972593 A CN 1972593A CN A200480040601X A CNA200480040601X A CN A200480040601XA CN 200480040601 A CN200480040601 A CN 200480040601A CN 1972593 A CN1972593 A CN 1972593A
Authority
CN
China
Prior art keywords
irna
gene
sequence
cells
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA200480040601XA
Other languages
English (en)
Chinese (zh)
Inventor
K·维尔斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Revivicor Inc
Original Assignee
Revivicor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Revivicor Inc filed Critical Revivicor Inc
Publication of CN1972593A publication Critical patent/CN1972593A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/054—Animals comprising random inserted nucleic acids (transgenic) inducing loss of function
    • A01K2217/058—Animals comprising random inserted nucleic acids (transgenic) inducing loss of function due to expression of inhibitory nucleic acid, e.g. siRNA, antisense
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/108—Swine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A01K2267/025—Animal producing cells or organs for transplantation
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/12—Applications; Uses in screening processes in functional genomics, i.e. for the determination of gene function
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/60—Vectors containing traps for, e.g. exons, promoters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Environmental Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA200480040601XA 2003-11-21 2004-11-22 干扰rna在生产转基因动物中的用途 Pending CN1972593A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52393803P 2003-11-21 2003-11-21
US60/523,938 2003-11-21

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2013103209599A Division CN103397019A (zh) 2003-11-21 2004-11-22 干扰rna在生产转基因动物中的用途

Publications (1)

Publication Number Publication Date
CN1972593A true CN1972593A (zh) 2007-05-30

Family

ID=34910676

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA200480040601XA Pending CN1972593A (zh) 2003-11-21 2004-11-22 干扰rna在生产转基因动物中的用途
CN2013103209599A Pending CN103397019A (zh) 2003-11-21 2004-11-22 干扰rna在生产转基因动物中的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2013103209599A Pending CN103397019A (zh) 2003-11-21 2004-11-22 干扰rna在生产转基因动物中的用途

Country Status (7)

Country Link
US (1) US10793873B2 (https=)
EP (2) EP2514826A3 (https=)
JP (1) JP2007512027A (https=)
CN (2) CN1972593A (https=)
AU (1) AU2004316293A1 (https=)
CA (1) CA2546853C (https=)
WO (1) WO2005081714A2 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108513580A (zh) * 2015-10-08 2018-09-07 哈佛学院董事及会员团体 多重基因组编辑
CN113227382A (zh) * 2018-11-08 2021-08-06 绿光生物科技股份有限公司 昆虫侵袭的控制
CN115011601A (zh) * 2022-06-27 2022-09-06 山东大学齐鲁医院 一种干扰JUND表达的shRNA、重组腺相关病毒载体及其应用
US12058986B2 (en) 2017-04-20 2024-08-13 Egenesis, Inc. Method for generating a genetically modified pig with inactivated porcine endogenous retrovirus (PERV) elements

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4948163B2 (ja) * 2003-05-23 2012-06-06 サーナ・セラピューティクス・インコーポレイテッド 化学修飾した低分子干渉核酸（ｓｉＮＡ）を使用する遺伝子発現のＲＮＡ干渉仲介抑制
CA2533259C (en) * 2003-07-21 2014-01-28 Lifecell Corporation Acellular tissue matrices made from galactose .alpha.-1,3-galactose-deficient tissue
EP1582591A3 (en) * 2004-02-27 2005-12-21 Bundesrepublik Deutschland vertreten durch das Bundesminsterium für Gesundheit, dieses vertr. durch das Robert-Koch-Institut Sirna and their use for knock down expression of porcine endogenous retrovirus
US20070033666A1 (en) * 2005-06-24 2007-02-08 Harris Reuben S Using cytosine deaminases to diminish retroelement transfer from pigs to humans
JP2007104969A (ja) * 2005-10-13 2007-04-26 Bio Think Tank Co Ltd ショートヘアピン型ＲＮＡ（ｓｈＲＮＡ）前駆体を産生するための核酸及びその利用
JP5832721B2 (ja) * 2007-03-14 2015-12-16 バイオンシル・エス．アール．エル．Ｂｉｏｎｓｉｌ Ｓ．Ｒ．Ｌ． 上皮腫瘍細胞における薬剤耐性のモジュレータ化合物
DK2164967T3 (en) 2007-05-31 2015-10-19 Univ Iowa Res Found Reduction of off-target rna interferenstoksicitet
JP5554231B2 (ja) * 2007-06-13 2014-07-23 コモンウェルス サイエンティフィック アンドインダストリアル リサーチ オーガナイゼーション トリの生産形質の改変
WO2010008562A2 (en) * 2008-07-16 2010-01-21 Recombinetics Methods and materials for producing transgenic animals
WO2010125117A2 (en) * 2009-04-29 2010-11-04 Ralph Wirtz A method to assess prognosis and to predict therapeutic success in cancer by determining hormone receptor expression levels
CN105911275B (zh) * 2009-08-14 2018-06-29 加利福尼亚大学董事会 诊断自闭症的试剂盒
US9420770B2 (en) 2009-12-01 2016-08-23 Indiana University Research & Technology Corporation Methods of modulating thrombocytopenia and modified transgenic pigs
JP2013534824A (ja) * 2010-06-24 2013-09-09 ジ・オハイオ・ステート・ユニバーシティ 標的化されたｍｉＲ−２９発現によりマウスにおいてモデル化された慢性リンパ性白血病
WO2012109667A1 (en) 2011-02-12 2012-08-16 University Of Iowa Research Foundation Therapeutic compounds
EP2698379A4 (en) * 2011-03-18 2015-04-29 Shanghai Inst Biol Sciences INSECTROSIVE PREPARATION AND METHODS BASED ON RNAI TECHNOLOGY
WO2013188358A1 (en) * 2012-06-12 2013-12-19 The General Hospital Corporation Miniature swine transgenic for one or more coagulation factors
WO2015066668A1 (en) 2013-11-04 2015-05-07 Lifecell Corporation Methods of removing alpha-galactose
CN104677866A (zh) * 2014-03-25 2015-06-03 中国科学院大连化学物理研究所 测定CP装载siRNA体系中siRNA释放的方法
EP3146051B8 (en) 2014-05-20 2019-11-27 University of Iowa Research Foundation Huntington's disease therapeutic compounds
CN104232670A (zh) * 2014-08-25 2014-12-24 中国水产科学研究院黑龙江水产研究所 一种采用鱼类转基因方法构建的基于鲤鱼mstn干涉载体及其构建方法
HK1254818A1 (zh) 2015-06-26 2019-07-26 The Regents Of The University Of California 抗原肽及其用於诊断和治疗自闭症的用途
CN106918697B (zh) * 2017-02-15 2018-07-31 中国医学科学院北京协和医院 一种预测ra药物疗效的诊断标志物及其应用
CN107760682B (zh) * 2017-10-18 2020-12-18 云南大学 一种可用于分子防治害虫的核酸序列及其应用
CN110628807B (zh) * 2018-05-30 2021-06-18 中国科学院植物研究所 盐角草SePSS蛋白及其编码基因与应用
US20210277421A1 (en) * 2018-08-06 2021-09-09 NemaMetrix, Inc Homologous Recombination Reporter Construct and Uses Thereof
US10883084B2 (en) 2018-10-05 2021-01-05 Xenotherapeutics, Inc. Personalized cells, tissues, and organs for transplantation from a humanized, bespoke, designated-pathogen free, (non-human) donor and methods and products relating to same
MX2021003866A (es) 2018-10-05 2021-09-08 Xenotherapeutics Inc Productos y metodos de xenotransplante.
CN110055253A (zh) * 2019-04-28 2019-07-26 复旦大学附属金山医院 一种针对人半胱氨酸蛋白酶抑制剂B的siRNA分子及其应用
US20220012673A1 (en) * 2020-07-13 2022-01-13 ZenDesk, Inc. Maintaining status information for customer-support agents across multiple channels
EP4256061A1 (en) * 2020-12-01 2023-10-11 ETH Zurich Dna constructs comprising alternative promoters
WO2022235971A2 (en) * 2021-05-06 2022-11-10 Systems Oncology, Llc Compositions for inhibiting growth of targeted cells
WO2022256294A1 (en) * 2021-06-01 2022-12-08 University Of Massachusetts Cas9 nickase-mediated gene editing
WO2023004365A1 (en) * 2021-07-20 2023-01-26 Sio Gene Therapies Inc. Vector constructs for delivery of nucleic acids encoding therapeutic proteasome activator complex subunits and methods of using the same
CN118581151B (zh) * 2024-05-29 2024-12-06 中国农业科学院兰州兽医研究所(中国动物卫生与流行病学中心兰州分中心) 一种猪becn1基因敲除细胞的构建方法及其应用
CN120608104B (zh) * 2025-08-12 2025-11-25 中国科学院水生生物研究所 lasp1基因在鱼类抗病毒免疫调控中的功能和应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4517338A (en) 1983-06-20 1985-05-14 Chiron Corporation Multiple reactor system and method for polynucleotide synthesis
US4888274A (en) 1985-09-18 1989-12-19 Yale University RecA nucleoprotein filament and methods
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
US5464764A (en) * 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
WO1999046388A1 (en) 1998-03-12 1999-09-16 Taisho Pharmaceutical Co., Ltd. Nucleic acid enzyme showing allosteric rna-cleaving activity on target rna
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
CN101818145A (zh) 1998-03-20 2010-09-01 联邦科学和工业研究组织 控制基因表达
AU5682999A (en) 1998-08-18 2000-03-14 Biotransplant Incorporated Molecular sequence of swine retrovirus and methods of use
EP1272630A2 (en) * 2000-03-16 2003-01-08 Genetica, Inc. Methods and compositions for rna interference
US20030084471A1 (en) * 2000-03-16 2003-05-01 David Beach Methods and compositions for RNA interference
ES2336887T5 (es) 2000-03-30 2019-03-06 Whitehead Inst Biomedical Res Mediadores de interferencia por ARN específicos de secuencias de ARN
US20030143597A1 (en) * 2000-12-28 2003-07-31 Finney Robert E. Methods for making polynucleotide libraries, polynucleotide arrays, and cell libraries for high-throughput genomics analysis
EP1386004A4 (en) 2001-04-05 2005-02-16 Ribozyme Pharm Inc MODULATION OF GENE EXPRESSION ASSOCIATED WITH INFLAMMATORY PROLIFERATION AND GROWTH OF NEURITIES BY METHODS INVOLVING NUCLEIC ACID
KR20040023596A (ko) * 2001-05-01 2004-03-18 도꾸리쯔교세이호진 상교기쥬쯔 소고겡뀨죠 신규 맥시자임
IL159756A0 (en) * 2001-07-12 2004-06-20 Univ Massachusetts IN VIVO PRODUCTION OF SMALL INTERFERING RNAs THAT MEDIATE GENE SILENCING
WO2003012052A2 (en) * 2001-07-30 2003-02-13 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Specific inhibition of gene expression by small double stranded rnas
JP4344858B2 (ja) * 2001-09-13 2009-10-14 カリフォルニア インスティチュート オブ テクノロジー 細胞内で抗ウイルス性小ｒｎａ分子を発現させる方法
US20030148519A1 (en) 2001-11-14 2003-08-07 Engelke David R. Intracellular expression and delivery of siRNAs in mammalian cells
JP2005538685A (ja) 2001-12-21 2005-12-22 トランザイム， インコーポレイテッド レンチウイルスベクターを使用して遺伝的に改変された動物を生成するための方法および組成物
CN1620508A (zh) 2001-12-21 2005-05-25 牛津生物医学（英国）有限公司 转基因生物
GB0130955D0 (en) 2001-12-24 2002-02-13 Cancer Res Ventures Expression system
EP1572902B1 (en) 2002-02-01 2014-06-11 Life Technologies Corporation HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
US20030203868A1 (en) * 2002-02-06 2003-10-30 Bushman Frederic D. Inhibition of pathogen replication by RNA interference
US20040045043A1 (en) 2002-05-20 2004-03-04 Finney Robert E. Compositions and methods for generating conditional knockouts
DK1534819T3 (da) 2002-08-21 2010-04-19 Revivicor Inc Griselignende dyr, som mangler enhver ekspression af funktionel alfa-1,3-galactosyltransferase
US20040072769A1 (en) * 2002-09-16 2004-04-15 Yin James Qinwei Methods for design and selection of short double-stranded oligonucleotides, and compounds of gene drugs
CN1276976C (zh) * 2003-10-30 2006-09-27 封江南 单一载体编码多个发夹结构小干扰性rna表达系统及其构建方法
EP1582591A3 (en) * 2004-02-27 2005-12-21 Bundesrepublik Deutschland vertreten durch das Bundesminsterium für Gesundheit, dieses vertr. durch das Robert-Koch-Institut Sirna and their use for knock down expression of porcine endogenous retrovirus

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108513580A (zh) * 2015-10-08 2018-09-07 哈佛学院董事及会员团体 多重基因组编辑
CN116064664A (zh) * 2015-10-08 2023-05-05 哈佛学院董事及会员团体 多重基因组编辑
US12133515B2 (en) 2015-10-08 2024-11-05 President And Fellows Of Harvard College Multiplexed genome editing
US12058986B2 (en) 2017-04-20 2024-08-13 Egenesis, Inc. Method for generating a genetically modified pig with inactivated porcine endogenous retrovirus (PERV) elements
CN113227382A (zh) * 2018-11-08 2021-08-06 绿光生物科技股份有限公司 昆虫侵袭的控制
US11932853B2 (en) 2018-11-08 2024-03-19 Greenlight Biosciences, Inc. Control of insect infestation
US12522825B2 (en) 2018-11-08 2026-01-13 Greenlight Biosciences, Inc. Control of insect infestation
CN115011601A (zh) * 2022-06-27 2022-09-06 山东大学齐鲁医院 一种干扰JUND表达的shRNA、重组腺相关病毒载体及其应用

Also Published As

Publication number Publication date
AU2004316293A1 (en) 2005-09-09
EP2514826A2 (en) 2012-10-24
EP2514826A3 (en) 2013-04-03
CN103397019A (zh) 2013-11-20
CA2546853A1 (en) 2005-09-09
EP1734811A4 (en) 2009-03-25
WO2005081714A2 (en) 2005-09-09
CA2546853C (en) 2020-04-21
US20050266561A1 (en) 2005-12-01
JP2007512027A (ja) 2007-05-17
US10793873B2 (en) 2020-10-06
WO2005081714A3 (en) 2006-11-16
EP1734811A2 (en) 2006-12-27

Similar Documents

Publication Publication Date Title
US10793873B2 (en) Use of interfering RNA in the production of transgenic animals
US11172658B2 (en) Porcine animals lacking expression of functional alpha 1, 3 galactosyltransferase
US10300112B2 (en) Transgenic ungulates expressing CTLA4-IG and uses thereof
EP1462525B1 (en) siRNA EXPRESSION SYSTEM AND PROCESS FOR PRODUCING FUNCTIONAL GENE KNOCKDOWN CELL OR THE LIKE USING THE SAME
KR20150014446A (ko) 세포 형질감염 방법
JP2022113700A (ja) ＣＲＩＳＰＲ－Ｃａｓゲノム編集に基づく、Ｆｅｌ ｄ１ノックアウト並びに関連組成物及び方法
JP2007525955A (ja) ブタｃｍｐ−ｎ−アセチルノイラミン酸ヒドロキシラーゼ遺伝子
AU2005243169A1 (en) Porcine Forssman synthetase protein, cDNA, genomic organization, and regulatory region
EP2201116B1 (en) Means and methods for shrna mediated conditional knockdown of genes
AU2015204349B2 (en) Use of interfering RNA in the production of transgenic animals
NZ547388A (en) Use of interfering RNA in the production of transgenic animals
AU2012205138A1 (en) Use of interfering RNA in the production of transgenic animals
EP3942298B1 (en) Method for increasing cell susceptibility to complement-mediated lysis
DA et al. interference.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20070530